XTalks

OCTOBER 20, 2023

Clinical-stage genome editing company Intellia Therapeutics has received clearance from the US Food and Drug Administration (FDA) for its Investigational New Drug (IND) application to start a pivotal phase III trial of NTLA-2001 for the treatment of transthyretin (ATTR) amyloidosis with cardiomyopathy.

In-Vivo 52

In-Vivo Gene Editing Trials Gene 52

XTalks

JANUARY 26, 2024

Innovations in Cancer Therapy CRISPR/Cas9, a groundbreaking gene-editing technology, has demonstrated significant potential in oncology, offering new avenues for cancer treatment. Clinical trials have demonstrated the potential of CRISPR/Cas9 in this field.

Research 118

Research Gene Editing Gene Genetics 118

XTalks

DECEMBER 20, 2023

This includes analyzing how drug combinations may impact individual patients or groups of patients before even entering a clinical trial. With a staggering 90 percent of drugs failing in clinical trials, AI has the potential to help improve these statistics. These companies are at various stages of research and clinical trials.

Life Science 119

Life Science Gene Editing Development Clinical Trials 119

pharmaphorum

JULY 1, 2021

Synthetic biology has grown exponentially in less than a decade, with CRISPR gene-editing as the key technology driving this through its use in areas like cancer, infectious diseases, and rare, undertreated indications. Alongside this, there is a need to take financial risks.

Gene Editing 88

Gene Editing Engineer Development Gene 88

XTalks

NOVEMBER 30, 2023

The safety and efficacy of Cabenuva were established through two randomized, open-label, controlled clinical trials involving 1,182 HIV-infected adults who were virologically suppressed (HIV-1 RNA less than 50 copies/mL) before initiating Cabenuva treatment. The Phase I trial for HB-500 is scheduled to start in the first half of 2024.

FDA Approval 111

FDA Approval Gene Therapy Gene Clinical Trials 111

WCG Clinical

NOVEMBER 17, 2023

Since then, however, certain genetic engineering technologies (e.g., CRISPR-based gene editing) have advanced to the point where cellular genomes can be edited without using viral vectors or any other materials subject to the NIH Guidelines and without integration of rsNA into the chromosome.

Genomics 52

Genomics Genome Gene Editing Genetic Engineering 52

Delveinsight

AUGUST 27, 2020

Freenome persists in getting strong financial support for its development work, with USD 270 million in new funds to push its cancer-detecting blood test via clinical trials and across the FDA’s finish line. Freenome secures USD 270 Million to boost its colorectal cancer blood test.

Vaccination 53

Vaccination Vaccine Research Trials 53

Delveinsight

SEPTEMBER 14, 2021

The outcomes will also be utilized to transition ADARx’s growing pipeline of research phase products into the clinic, initiating Phase 1 clinical trials for ADARx’s lead program. VOR33 comprises CRISPR genome-edited hematopoietic stem and progenitor cells , which have been engineered to exclude CD33.

RNA 67

RNA Clinical Trials Clinical Trials Drugs 67

XTalks

SEPTEMBER 20, 2024

Vittoria Biotherapeutics is a clinical-stage cell therapy company that incorporates the latest advancements in cell therapy and gene editing with a unique approach that potentially overcomes some of the issues with this therapeutic modality. Its therapeutic pipeline targets unmet needs in oncology and autoimmune disease.

Gene Editing 52

Gene Editing Manufacturing Gene In-Vivo 52

Bioengineer

JULY 23, 2021

Credit: Texas A&M Engineering. The team has recently submitted a patent disclosure with the Texas A&M Engineering Experiment Station. Gang Bao, a gene editing expert from Rice University. Video credit: Dr. Abhishek Jain/Texas A&M Engineering. ” ###. Media Contact Amy Halbert ahalbert@tamu.edu.

Engineer 52

Engineer Gene Editing Clinical Trials Clinical Trials 52

pharmaphorum

SEPTEMBER 28, 2022

” ArsenalBio’s platform makes use of automation, large-scale genome engineering, using technologies like CRISPR-based gene-editing, and machine learning and artificial intelligence algorithms to design, build, and test cell therapies.

Gene Editing 59

Gene Editing Genomics Genome Engineer 59

Bioengineer

JULY 19, 2021

Appendiceal cancer is historically resistant to systemic chemotherapy, and the effect of immunotherapy is essentially unknown because clinical trials are difficult to perform due to lack of adequate patient numbers, resulting in a lack of data and limited research models.

Engineer 52

Engineer Medicine Clinical Trials Clinical Trials 52

XTalks

MARCH 28, 2024

Early clinical trials have shown promising results and this therapy could become a valuable addition towards CRC treatment in the future. Gene Editing and CAR T-Cell Therapy Genetic engineering technologies, such as CRISPR-Cas9, are providing newer potential avenues for cancer treatment.

Gene Editing 59

Gene Editing Life Science Clinical Trials Clinical Trials 59

pharmaphorum

DECEMBER 21, 2022

As part of the acquisition, Kite will assume responsibility for continuing the R&D collaboration between Tmunity and Penn, which includes options and licenses to cell engineering and manufacturing technologies invented and developed in the university’s laboratories. Image by Anja from Pixabay .

Gene Editing 52

Gene Editing Licensing Licensing Manufacturing 52

The Pharma Data

JANUARY 24, 2021

With a presidential inauguration and a federal holiday, it wasn’t an enormously busy week for clinical trial news, but there was a fair amount, nonetheless. It inked a deal with the National Institute of Allergy and Infectious Diseases (NIAID) to launch a Phase I trial. Read on to see. COVID-19-Related. Non-COVID-19-Related.

Trials 52

Trials Allergies In-Vitro Antibody 52

The Pharma Data

NOVEMBER 22, 2021

State-of-the-art R&D facility designed to foster collaboration across world-class science ecosystem Sustainable environmental engineering aligned to Company’s zero carbon future. This enhancement moves AstraZeneca well above the current assiduity average success rate of 14 in the 2018-2020 timeframe.4.

Gene Editing 52

Gene Editing Engineer Production Scientist 52

Advarra

NOVEMBER 29, 2022

Bottlenecks in the manufacturing process, supply chain issues such as accessibility of good manufacturing practice (GMP)-grade reagents, and shortages of qualified scientists and engineers have caused many therapies to fail at critical stages of the clinical development pipeline. Improving Communication Between FDA and Sponsors.

Gene Therapy 52

Gene Therapy Gene Production Clinical Trials 52

pharmaphorum

NOVEMBER 2, 2021

In 2019, there were 57 bsAb candidates in clinical trials, against both haematological and solid tumours. In the pipeline , Amgen has BiTE molecules targeting seven types of cancer in clinical trials, as well as further structures in the design stage. Simplified schematic overview of the proposed mechanisms of action for bsAbs.

Antibody 52

Antibody Immune Response Production Engineer 52

XTalks

DECEMBER 24, 2020

From rare disease drug approvals to treatments involving immunotherapies and gene therapies and awarding of a Nobel Prize to the inventors of the gene-editing tool CRISPR, 2020 was a year of great activity and productivity despite the backdrop of the pandemic. CRISPR Gene Editing Inventors Win Nobel Prize.

Life Science 111

Life Science Vaccine Vaccination Gene 111

XTalks

NOVEMBER 29, 2024

The acquisition also grants Roche access to Poseida’s P-CD19CD20-ALLO1, a dual-target CAR-T therapy currently in Phase I trials for B-cell malignancies. Additionally, Poseida’s solid tumor program, P-MUC1C-ALLO1, is advancing in Phase I trials, targeting antigen-expressing tumors with promising early results.

Gene Therapy 100

Gene Therapy Gene Gene Editing Genetic Engineering 100

XTalks

JANUARY 6, 2025

For example, antisense oligonucleotide (ASO)-based therapies have gained traction, with 100 Phase I clinical trials initiated and around 25 percent of these advancing to Phase II or Phase III trials in recent years.

Gene Therapy 111

Gene Therapy RNA Gene Editing Gene 111

XTalks

FEBRUARY 11, 2025

Gene therapy has shown promise in treating cancers that are particularly difficult to manage such as neuroblastoma and Wilms tumor using CAR-T cell therapy, CRISPR-Cas9 gene editing and RNA-based interventions to target genetic drivers of disease.

Gene Therapy 66

Gene Therapy Clinical Trials Clinical Trials Trials 66